Brief: Gossamer Bio Q1 EPS USD -0.2
18/05/2026 12:00
May 18 (Reuters) - Gossamer Bio Q1 net income USD -46.664 million. Q1 operating income USD -44.866 million Q1 operating expenses USD 61.821 million Q1 basic EPS USD -0.2
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing